(Press-News.org) Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat the disease. The study was led by Dr. Donald Kohn, professor of pediatrics and of microbiology, immunology and molecular genetics.
Sickle cell disease causes the body to produce red blood cells that are formed like the crescent-shaped blade of a sickle, which hinders blood flow in the blood vessels and deprives the body's organs of oxygen.
Kohn introduced an anti-sickling gene into the hematopoietic stem cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle. The breakthrough gene therapy technique for sickle cell disease is scheduled to begin clinical trials by early 2014. The study was published online today ahead of press in the Journal of Clinical Investigation.
Kohn's gene therapy approach, which uses hematopoietic stem cells from a patient's own blood, is a revolutionary alternative to current sickle cell disease treatments as it creates a self-renewing normal blood cell by inserting a gene that has anti-sickling properties into hematopoietic stem cells. This approach also does not rely on the identification of a matched donor, thus avoiding the risk of rejection of donor cells. The anti-sickling hematopoietic stem cells are transplanted back into the patient's bone marrow and multiply the corrected cells that make red blood cells without sickling.
"The results demonstrate that our technique of lentiviral transduction is capable of efficient transfer and consistent expression of an effective anti-sickling beta-globin gene in human sickle cell disease bone marrow progenitor cells, which improved the physiologic parameters of the resulting red blood cells," Kohn said.
Kohn and colleagues found that in the laboratory the hematopoietic stem cells produced new non-sickled blood cells at a rate sufficient for significant clinical improvement for patients. The new blood cells survive longer than sickled cells, which could also improve treatment outcomes.
Sickle cell disease mostly affects people of Sub-Saharan African descent, and more than 90,000 patients in the U.S. have been diagnosed. It is caused by an inherited mutation in the beta-globin gene that makes red blood cells change from their normal shape, which is round and pliable, into a rigid, sickle-shaped cell. Normal red blood cells are able to pass easily through the tiniest blood vessels, called capillaries, carrying oxygen to organs such as the lungs, liver and kidneys. But due to their rigid structure, sickled blood cells get stuck in the capillaries.
Current treatments include transplanting patients with donor hematopoietic stem cells, which is a potential cure for sickle cell disease, but due to the serious risks of rejection, only a small number of patients have undergone this procedure and it is usually restricted to children with severe symptoms.
###
This study was supported in part by a Disease Team I Award from the California Institute for Regenerative Medicine, the state's stem cell research agency, which was created by a voter initiative in 2004. The purpose of the disease team program is to support research focused on one particular disease that leads to the filing of an investigational new drug application with the FDA within four years. The program is designed to speed translational research — research that takes scientific discoveries from the laboratory to the patient bedside. This requires new levels of collaboration between basic laboratory scientists, medical clinicians, biotechnology experts and pharmacology experts, to name a few.
Other support came from UCLA's Broad Stem Cell Research Center and Jonsson Comprehensive Cancer Center, and from the Ruth L. Kirschstein National Research Service Award.
The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research: UCLA's stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Broad Stem Cell Research Center is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science.
For more news, visit the UCLA Newsroom and follow us on Twitter.
UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
2013-07-02
ELSE PRESS RELEASES FROM THIS DATE:
Bioengineering fungi for biofuels and chemicals production
2013-07-02
New Rochelle, NY, July 1, 2013—Among the increasingly valuable roles fungi are playing in the biotechnology industry is their ability to produce enzymes capable of releasing sugars from plants, trees, and other forms of complex biomass, which can then be converted to biofuels and biobased chemicals. Advances in fungal biology and in bioengineering fungal systems industrial applications are explored in a series of articles in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available on the Industrial Biotechnology ...
Researchers use immunocytochemistry to determine ALK status
2013-07-02
DENVER – Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers. The standard procedure for detection of predictive anaplastic lymphoma kinase (ALK)-rearrangements is fluorescence in situ hybridization (FISH), but FISH is both expensive and often challenging to interpret. Lung cancer is often diagnosed by cytology necessitating predictive molecular marker analyses on cytological specimens.
Now research published in the August issue ...
Researchers find 2 new methods to determine ALK status
2013-07-02
DENVER – The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers. Anaplastic lymphoma kinase (ALK), a tyrosine kinase, is a more recently characterized cancer biomarker in non–small-cell lung cancer (NSCLC). To identify
NSCLC patients with ALK gene rearrangement in clinical trials, researchers have used the methods known as fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC). While IHC is a less ...
Study shows SBRT for stage I NSCLC safe and effective
2013-07-02
DENVER – Stereotactic body radiotherapy (SBRT) is considered the treatment of choice for early-stage non–small-cell lung cancer (NSCLC) if patients are inoperable because of additional medical conditions. This is based on several prospective phase II trials, which reported consistently high rates of local tumor control. However, these studies only included small number of patients, the methodology of SBRT varied between the studies and SBRT was mainly practiced in specialized centers. Therefore, safety and efficacy of SBRT practiced in routine clinical practice outside ...
Silver Fire, New Mexico
2013-07-02
The Silver Fire in southern New Mexico continues to generate a lot of smoke, as seen recently on imagery from NASA's Terra satellite.
The Silver Fire is burning in the Gila National Forest. As of July 1, the fire had consumed 133,625 acres. It began on June 7 from a lightning strike near Kingston, New Mexico. According to the multi-agency Incident Information System called Inciweb, the fire was 50 percent contained on July 1.
The Moderate Resolution Imaging Spectroradiometer (MODIS) instrument aboard NASA's Terra satellite has infrared capabilities that can detect ...
Pregnancy as window to future health
2013-07-02
Physicians with the Society for Maternal-Fetal Medicine released a paper today that provides significant insight into future health conditions that women are likely to experience, and that can be detected early based on information relating to the course of pregnancy. The paper, Pregnancy as a Window to Future Health: The development of complications in pregnancy provides a new window of opportunity for early heart disease risk screening and intervention for women, acknowledges that, for most women, the demands of pregnancy on the cardiovascular and metabolic systems are ...
NASA sees heavy rainfall as Typhoon Rumbia heads for landfall in China
2013-07-02
Typhoon Rumbia developed from a low pressure area east of the Philippines and crossed the country from east to west before moving into the South China Sea. NASA's TRMM satellite flew over Rumbia as it nears southeastern China and identified areas of heavy rainfall in the southern quadrant of the storm.
On Sunday, June 30, NASA infrared satellite imagery revealed tightly curved bands of thunderstorms over the southern quadrant of the storm were wrapping into the northern quadrant of the low-level center. However, in the northwestern quadrant, the quadrant that will make ...
Researchers pinpoint sources of fibrosis-promoting cells that ravage organs
2013-07-02
HOUSTON – Scientists have tracked down and quantified the diverse origins of cells that drive fibrosis, the incurable, runaway wound-healing that scars and ultimately destroys organs such as the lungs, liver and kidneys.
Findings from research conducted at Beth Israel Deaconess Medical Center, Harvard Medical School and Massachusetts Institute of Technology in Boston and continued at The University of Texas MD Anderson Cancer Center are reported in an advance online publication at Nature Medicine on June 30.
"Answering a fundamental question about the origin of these ...
Surprise superconductor
2013-07-02
Washington, D.C.—Superconductivity is a rare physical state in which matter is able to conduct electricity—maintain a flow of electrons—without any resistance. This phenomenon can only be found in certain materials under specific low-temperature and high-pressure conditions. Research to create superconductors at higher temperatures has been ongoing for two decades with the promise of significant impact on electrical transmission.
New research from a team led by Choong-Shik Yoo at Washington State University—and including Carnegie's Viktor Struzhkin, Takaki Muramatsu, ...
Altitude sickness may hinder ethnic integration in the world's highest places
2013-07-02
Ethnic segregation in nations straddling the world's steepest terrains may be reinforced by the biological tolerance different peoples have to altitude, according to one of the first studies to examine the effect of elevation on ethnic demographics.
Research from Princeton University published in the journal Applied Geography suggests that people native to low-lying areas can be naturally barred from regions such as the Tibetan Plateau, the Andes or the Himalayas by altitude sickness, which is caused by low oxygen concentration in the air and can be life-threatening. ...